Nobutsune Ishikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nobutsune Ishikawa has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Koji Iida
Department of Neurosurgery, Epilepsy Center, Hiroshima University, Graduate School of Biomedical and Health Sciences, Japan
2 shared publications- Akihiro Shimotake
Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication - Akio Ikeda
Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication Akira Hashizume
1 shared publicationAkira Kato
Suzugamine Facility for Persons with Severe Motor and Intellectual Disabilities, Hiroshima, Japan
1 shared publication- Akitake Okamura
Department of Neurosurgery Hiroshima University Hospital Hiroshima Japan
1 shared publication
Latest Publications
- 30 December 2024
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 56 (02) , 119-124
Efficacy and Tolerability of Lacosamide in Pediatric and Young Adult Epilepsy Patients with Severe Motor and Intellectual Disabilities
Objective Epilepsy is common among patients with severe motor and intellectual disabilities (SMID) patients, often taking a prolonged and intractable course. Lacosamide (LCM) is widely used to treat epilepsy in both adults and children. We assess the efficacy and tolerability of LCM among pediatric and young adult epilepsy patients with SMID who suffer from intractable seizures. Methods This retrospective analysis reviewed the medical records of SMID patients undergoing LCM treatment for more than a year. The study included 24 patients (14 males) aged 3 to 29 years. Epilepsy was classified as focal in 17 patients, generalized in 4 patients, and combined generalized and focal in 3 patients. Results The retention rates were 70.8%, 65%, and 52.9% at 1, 2, and 3 years after LCM initiation, respectively. The 50% responder rate (achieving >50% seizure reduction) for LCM treatment was 50%, with two patients experiencing complete seizure control (absence of seizures for 6 months before the follow-up visit). The 50% responders included a higher proportion of patients with focal epilepsy (58.8%) compared to those with generalized epilepsy (25.0%). Treatment-emergent adverse events (TEAEs) included somnolence in five patients and nausea in two patients. TEAEs, particularly nausea, developed within 1 month after treatment initiation in two patients, leading to LCM discontinuation. Conclusion LCM demonstrated good efficacy for intractable epilepsy in pediatric and young adult SMID patients. It was generally well-tolerated, resulting in a favorable retention rate. LCM emerged as a useful antiseizure medication for epilepsy treatment in pediatric and young adult SMID patients.
- 30 December 2024
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 56 (02) , 119-124
Efficacy and Tolerability of Lacosamide in Pediatric and Young Adult Epilepsy Patients with Severe Motor and Intellectual Disabilities
Objective Epilepsy is common among patients with severe motor and intellectual disabilities (SMID) patients, often taking a prolonged and intractable course. Lacosamide (LCM) is widely used to treat epilepsy in both adults and children. We assess the efficacy and tolerability of LCM among pediatric and young adult epilepsy patients with SMID who suffer from intractable seizures. Methods This retrospective analysis reviewed the medical records of SMID patients undergoing LCM treatment for more than a year. The study included 24 patients (14 males) aged 3 to 29 years. Epilepsy was classified as focal in 17 patients, generalized in 4 patients, and combined generalized and focal in 3 patients. Results The retention rates were 70.8%, 65%, and 52.9% at 1, 2, and 3 years after LCM initiation, respectively. The 50% responder rate (achieving >50% seizure reduction) for LCM treatment was 50%, with two patients experiencing complete seizure control (absence of seizures for 6 months before the follow-up visit). The 50% responders included a higher proportion of patients with focal epilepsy (58.8%) compared to those with generalized epilepsy (25.0%). Treatment-emergent adverse events (TEAEs) included somnolence in five patients and nausea in two patients. TEAEs, particularly nausea, developed within 1 month after treatment initiation in two patients, leading to LCM discontinuation. Conclusion LCM demonstrated good efficacy for intractable epilepsy in pediatric and young adult SMID patients. It was generally well-tolerated, resulting in a favorable retention rate. LCM emerged as a useful antiseizure medication for epilepsy treatment in pediatric and young adult SMID patients.
- Open Access
- 5 October 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 125, 108361
Risk factors for psychological distress in electroencephalography technicians during the COVID-19 pandemic: A national-level cross-sectional survey in Japan
- 5 October 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 125, 108361
Open AccessRisk factors for psychological distress in electroencephalography technicians during the COVID-19 pandemic: A national-level cross-sectional survey in Japan
- Open Access
- 1 June 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 24
Interpersonal communication skills related to seizure outcomes in pediatric patients with vagus nerve stimulation
- 1 June 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 24
Open AccessInterpersonal communication skills related to seizure outcomes in pediatric patients with vagus nerve stimulation
- 2 April 2019
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 50 (03) , 160-163
High Incidence of Renal Stones in Severely Disabled Children with Epilepsy Treated with Topiramate
Purpose This study was aimed to assess the accurate incidence of renal stones in severely disabled children treated with topiramate (TPM). Method We reviewed the medical records of severely disabled children with epilepsy under 15 years old who underwent radiological examinations to investigate urinary stones. The study enrolled 26 patients who were divided into two groups. One group had been treated with TPM for at least 1 year and the other had not been treated with TPM, zonisamide, acetazolamide, or other diuretic drugs. We collected parameters from the medical records and compared the groups. Results All participants were evaluated radiologically, with computed tomography (CT) in two patients, ultrasonography in 22 patients, and both in two. No patient had any morphological abnormality of the kidneys and history of urinary tract infection. There were no significant differences in sex, age, body weight, or feeding manner between the groups, while the incidence of renal stones or calcifications was significantly higher in the TPM-treated group (60 vs. 0%; p = 0.00241). Conclusion There is a high incidence of renal stone formation in severely disabled children treated with TPM.
- 2 April 2019
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 50 (03) , 160-163
High Incidence of Renal Stones in Severely Disabled Children with Epilepsy Treated with Topiramate
Purpose This study was aimed to assess the accurate incidence of renal stones in severely disabled children treated with topiramate (TPM). Method We reviewed the medical records of severely disabled children with epilepsy under 15 years old who underwent radiological examinations to investigate urinary stones. The study enrolled 26 patients who were divided into two groups. One group had been treated with TPM for at least 1 year and the other had not been treated with TPM, zonisamide, acetazolamide, or other diuretic drugs. We collected parameters from the medical records and compared the groups. Results All participants were evaluated radiologically, with computed tomography (CT) in two patients, ultrasonography in 22 patients, and both in two. No patient had any morphological abnormality of the kidneys and history of urinary tract infection. There were no significant differences in sex, age, body weight, or feeding manner between the groups, while the incidence of renal stones or calcifications was significantly higher in the TPM-treated group (60 vs. 0%; p = 0.00241). Conclusion There is a high incidence of renal stone formation in severely disabled children treated with TPM.